Fragmento

In the field of hepatitis C treatment, currently almost all past issues are solved, including treatment of special populations. Nevertheless, some aspects remain unanswered, such as the controversial decision to treat pre vs. post-liver transplantation (LT), the “point of no return” for improvement of hepatic function after antiviral treatment, and optimizing treatment outcomes in some subgroups like genotype 3 infection in hemodialysis patients. We read with interest the article by Eric M. Yoshida, et al., which is a post-hoc analysis of the persistence of viral response (pTVR) after LT in patients included in the SOLAR trials who received antiviral treatment and subsequently underwent LT. In the study by Yoshida, et al., all 17 were decompensated cirrhotic patients (Child B or C) with median MELD score of 16 who started treatment with Ledipasvir/Sofosbuvir plus ribavirin (RBV) before LT. Of these, 10 patients completed their planned treatment duration before LT, while 7 underwent LT before completing the 12 or 24 weeks of planned antiviral treatment. Seventy-six percent of patients completed at least 12 weeks of antiviral treatment. As a result, all 17 patients achieved pTVR, although one died shortly after LT (unrelated to study drugs), leading to a 94% rate of pTVR-12.

Palabras clave:

2017-05-03   |   579 visitas   |   Evalua este artículo 0 valoraciones

Vol. 16 Núm.3. Mayo-Junio 2017 Pags. 322-323 Ann Hepatol 2017; 16(3)